MoonLake Immunotherapeutics (MLTX) Interest Expenses (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Interest Expenses of $2.3 million for Q1 2026, up 525.0% year-over-year from $368000.0 in Q1 2025, and up 5.12% quarter-over-quarter from $2.2 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Interest Expenses (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Interest Expenses history runs 6 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 525.0% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.1 million (up 593.38% YoY), while the FY2025 annual figure was $7.2 million, down 70.93% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.3 million, up from $2.2 million in the prior quarter.
- The five-year high for Interest Expenses was $25.6 million in Q2 2025, with the low at $657.0 in Q1 2022.
- The 5-year median for Interest Expenses is $212418.0 (2023), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses slumped 99.42% in 2022, then jumped 12265.74% in 2025.
- MoonLake Immunotherapeutics' Interest Expenses stood at $33757.0 in 2022, then jumped by 412.32% to $172945.0 in 2023, then surged by 48.38% to $256612.0 in 2024, then jumped by 752.65% to $2.2 million in 2025, then grew by 5.12% to $2.3 million in 2026.
- Business Quant data shows MLTX's Interest Expenses at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 17.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.01 Mn |
| Jun 30, 2026 | 17.01 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | 25.61 Mn |
| Jun 30, 2025 | 25.61 Mn |
| Mar 31, 2025 | 368,000.00 |
| Mar 31, 2025 | 368,000.00 |
| Dec 31, 2024 | 256,612.00 |
| Dec 31, 2024 | 256,612.00 |
| Sep 30, 2024 | 3.58 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 207,064.00 |
| Jun 30, 2024 | 207,064.00 |
| Mar 31, 2024 | 364,000.00 |
| Mar 31, 2024 | 364,000.00 |